Francis Dailey

Francis Dailey

Auto-generated profile, based on publicly available information

Francis Dailey

Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Missouri-Columbia, Missouri, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2017 in JMIR Mental Health
Verified
Journal Article
Open access
VTVartan C Tashjian
Vartan C Tashjian
SMSasan Mosadeghi
Sasan Mosadeghi
AHAmber R Howard
Amber R Howard
MLMayra Lopez
Mayra Lopez
TDTaylor Dupuy
Taylor Dupuy
BSBrennan Spiegel
Brennan Spiegel
Background: Improvements in software and design and reduction in cost have made virtual reality (VR) a practical tool for immersive, three-dimensional (3D), multisensory experiences that distract patients from painful stimuli. Objective: The objective of the study was to measure the impact of a onetime 3D VR intervention versus a two-dimensional (2D) distraction video for pain in hospitalized patients. Methods: We conducted a comparative cohort study in a large, urban teaching hospital in medical inpatients with an average pain score of ≥3/10 from any cause. Patients with nausea, vomiting, dementia, motion sickness, stroke, seizure, and epilepsy and those placed in isolation were excluded. Patients in the intervention cohort viewed a 3D VR experience designed to reduce pain using the Samsung Gear Oculus VR headset; control patients viewed a high-definition, 2D nature video on a 14-inch bedside screen. Pre- and postintervention pain scores were recorded. Difference-in-difference scores and the proportion achieving a half standard deviation pain response were compared between groups. Results: There were 50 subjects per cohort (N=100). The mean pain reduction in the VR cohort was greater than in controls (−1.3 vs −0.6 points, respectively; P=.008). A total of 35 (65%) patients in the VR cohort achieved a pain response versus 40% of controls (P=.01; number needed to treat=4). No adverse events were reported from VR. Conclusions: Use of VR in hospitalized patients significantly reduces pain versus a control distraction condition. These results indicate that VR is an effective and safe adjunctive therapy for pain management in the acute inpatient setting; future randomized trials should confirm benefit with different visualizations and exposure periods. Trial Registration: Clinicaltrials.gov NCT02456987; https://clinicaltrials.gov/ct2/show/NCT02456987 (Archived by WebCite at http://www.webcitation.org/6pJ1P644S)

1 December 2019 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
FDFrancis E Dailey
Francis E Dailey
ETErica P Turse
Erica P Turse
Ebubekir DaglilarEbubekir Daglilar
Ebubekir Daglilar
Veysel TahanVeysel Tahan
Veysel Tahan

1 December 2019 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
ETErica P Turse
Erica P Turse
FDFrancis E Dailey
Francis E Dailey
YGYezaz A Ghouri
Yezaz A Ghouri
Veysel TahanVeysel Tahan
Veysel Tahan

1 April 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
FMFolasade P. May
Folasade P. May
MRMark W. Reid
Mark W. Reid
SCSamuel Ethan Cohen
Samuel Ethan Cohen
FDFrancis Dailey
Francis Dailey
BSBrennan M.R. Spiegel
Brennan M.R. Spiegel

26 October 2018 in World Journal of Clinical Cases
Verified
Journal Article
Open access
ETErica P Turse
Erica P Turse
FDFrancis E Dailey
Francis E Dailey
MNMaliha Naseer
Maliha Naseer
EPEdward K Partyka
Edward K Partyka
Veysel TahanVeysel Tahan
Veysel Tahan
Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi-approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.